Sierra Oncology Inc. (SRRA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for SRRA in the last 30 days. The most recent was published Jul 18, 2022.

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.

Latest news

25 items

SRRA FAQ

8 questions
  • What does Sierra Oncology Inc. do?
    Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its...
  • What is the latest news on SRRA?
    Quantisnow has not tracked any new filings, ratings or press releases for SRRA in the last 30 days. The most recent wire item was published on July 18, 2022.
  • Where does SRRA stock trade?
    Sierra Oncology Inc. (SRRA) is listed on NASDAQ.
  • What sector and industry is SRRA in?
    Sierra Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Sierra Oncology Inc. go public?
    Sierra Oncology Inc. (SRRA) completed its IPO in 2015.
  • What are analysts saying about SRRA?
    Sierra Oncology Inc. has had 4 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $51.00 price target on 2022-01-31. Recent price targets range from $33.00 to $51.00.
  • What companies are similar to SRRA?
    Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC). Compare SRRA side-by-side with any of them on Quantisnow.
  • How can I track SRRA on Quantisnow?
    Quantisnow aggregates Sierra Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRRA to receive live email and push alerts on every new disclosure.